To the Editor: In a valuable review of low-molecular-weight heparins (LMWH), Eikelboom and Hankey1 stray off the beaten path into the unwelcoming area of obstetric therapeutics — a notoriously hostile environment replete with traps and hazards. Their statement that "low-molecular-weight heparins are being used increasingly in pregnant women with prosthetic heart valves and for the prevention and treatment of venous thromboembolism" is contentious and requires considerable qualification.
The full article is accessible to AMA
members and paid subscribers.
Login to MJA or subscribe now.
Correspondence:
- 1. Eikelboom JW, Hankey GJ. Low molecular weight heparins and heparinoids. Med J Aust 2002; 177: 379-383. <eMJA full text>
- 2. Anticoagulation in pregnancy and the puerperium. Med J Aust 2001; 175: 258-263. <eMJA full text>
- 3. Ginsberg J, Greer I, Hirsh J. Use of antithrombotic agents during prenancy. Chest 2001; 119: 122S-131S.
Online responses are no longer available. Please refer to our instructions for authors page for more information.